284462-45-9

Basic information

• Product Name: 4-CHLORO-2-METHOXY-5-(TRIFLUOROMETHYL)-BENZENAMINE
• Synonyms: 4-CHLORO-2-METHOXY-5-(TRIFLUOROMETHYL)-BENZENAMINE
• CAS NO: 284462-45-9
• Molecular Formula: C₈H₇ClF₃NO
• Molecular Weight: 225.5954896
• EINECS: -0
• Mol File: 284462-45-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-CHLORO-2-METHOXY-5-(TRIFLUOROMETHYL)-BENZENAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-2-METHOXY-5-(TRIFLUOROMETHYL)-BENZENAMINE(284462-45-9)
• EPA Substance Registry System: 4-CHLORO-2-METHOXY-5-(TRIFLUOROMETHYL)-BENZENAMINE(284462-45-9)

Safety Data

• Hazardous Substances Data: 284462-45-9(Hazardous Substances Data)

Upstream product

• 646989-36-8 1-chloro-5-methoxy-4-nitro-2-(trifluoromethyl)benzene 
• 284462-72-2 C₁₀H₉ClF₃NO₂ 

Downstream Products

• 884340-27-6 phenyl 4-chloro-2-methoxy-5-(trifluoromethyl)phenylcarbamate 
• 284462-83-5 4-(2-(N-methylcarbamoyl)-pyridin-4-yloxy)-3-chloroaniline 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 284462-44-8 4-(4-amino-3-chloro-phenoxy)-pyridine-2-carboxylic acid methylamide 

Relevant articles and documents

IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS

The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B-RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formula (I): wherein: J is independently -O- or -NRN1-; RN1, if present, is independently -H or a substituent; RN2 is independently -H or a substituent; Y is independently -CH= or -N=; Q is independently -(CH2)j-M-(CH2)k- wherein: j is independently 0, 1 or 2; k is independently 0, 1, or 2; j+k is 0, 1, or 2; M is independently -O-, -S-, -NH-, -NMe-, or -CH2-; each of RP1, RP2, RP3, and RP4 is independently -H or a substituent; and additionally RP1 and RP2 taken together may be -CH=CH-CH=CH-; L is independently: a linker group formed by a chain of 2, 3, or 4 linker moieties; each linker moiety is independently -CH2-,-NRN-, -C(=X)-, or -S(=O)2-; exactly one linker moiety is -NRN-, or: exactly two linker moieties are -NRN-; exactly one linker moiety is -C(=X)-, and no linker moiety is -S(=O)2-; or: exactly one linker moiety is -S(=O)2-, and no linker moiety is -C(=X)-; no two adjacent linker moieties are -NRN-; X is independently =O or =S; each RN is independently -H or a substituent; A is independently: C6-14carboaryl, C5-14heteroaryl, C3-12carbocyclic, C3-12heterocyclic; and is independently unsubstituted or substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.

OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.